Flow cytometric typing of B-cell Non Hodgkin lymphoma;Durchflußzytometrische typisierung der B-zell Non-Hodgkin-Lymphome

LaboratoriumsMedizin

Volumn 28, Issue 5, 2004, Pages 410-423

  Bettelheim, Peter ^a,d   Diem, Heinz ^b   Nebe, Thomas ^c  

^a Inst f Labormedizin   (Austria)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d OTTO WAGNER HOSPITAL   (Austria)

Author keywords

Chronic lymphocytic leukemia (CLL); Diffuse large cell lymphoma (DLCL); Flow cytometry; Follikular lymphoma (FL); Hairy cell leukemia (HCL); Mantle cell lymphoma (ML); Multiple myeloma (MM); Nodale marginal zone B lymphoma (NMZL); Non Hodgkin lymphoma (NHL)

Indexed keywords

CD103 ANTIGEN; CD19 ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; CD23 ANTIGEN; CD24 ANTIGEN; CD38 ANTIGEN; CD5 ANTIGEN; CD79B ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; LEUKOSIALIN; PROTEIN KINASE ZAP 70; SYNDECAN 1;

ANTIGEN EXPRESSION; B CELL LYMPHOMA; CHRONIC LYMPHATIC LEUKEMIA; FLOW CYTOMETRY; FOLLICULAR LYMPHOMA; HAIRY CELL LEUKEMIA; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; LYMPHOMA CELL; LYMPHOPLASMOCYTIC LYMPHOMA; MANTLE CELL LYMPHOMA; MINIMAL RESIDUAL DISEASE; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; MULTIPLE MYELOMA; NODAL MARGINAL ZONE B LYMPHOMA; NONHODGKIN LYMPHOMA; PROGNOSIS; REVIEW; SPLEEN TUMOR; SPLENIC MARGINAL ZONE LYMPHOMA; TUMOR CLASSIFICATION; TUMOR DIAGNOSIS; WORLD HEALTH ORGANIZATION;

EID: 8444225033     PISSN: 03423026     EISSN: None     Source Type: Journal    
DOI: 10.1515/LabMed.2004.056     Document Type: Review

References (36)

1. Jaffe ES, Harris NL, Stein H, Vardiman JW. Tumours of haematopoietic and lymphoid tissues. World Health Organization classification of tumours. 2001; IARC Press, Lyon.
2. Sanchez ML, Almeida J, Vidriales B, Lopz-Berges MC, Garcia-Marcos MA, Moro MJ, et al. Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation. Leukemia 2002;16:1460-9.
3. Matutes E, Owusu-Ankomah K, Morilla R, Garcia Marco J, Houlihan A, Que TH, Catovsky D. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 1994;8:1640-5.
4. Mauro FR, Gentile M, Mancini F, Giannarelli D, Guarini A, De Propriis MS, et al. Prognostic significance of lymphocyte morphology in patients with advanced chronic lymhpocytic leukemia treated with first line therapy of fludarabine + prednisone. Haematologica 2002;87:561-2.
5. Frater JL, McCarron KF, Hammel JP, Shapiro JL, Miller ML, Tubbs RR, et al. Typical and atypical chronic lymphocytic leukemia differ clinically and immunophenotypically. Am J Clin Pathol 2001;116:655-64.
6. Cuneo A, Rigolin GM, Bigoni R, De Angeli C, Veronese A, Cavazzini F, et al. Chronic lymphocytic leukemia with 6q-shows distinct hematological features and intermediate prognosis. Leukemia 2004;18:476-83.
7. Schlette E, Medeiros LJ, Keating M, Lai R. CD79b expression in chronic lymphocytic leukemia. Association with trisomy 12 and atypical immunophenotype. Arch Pathol Lab Med 2003;127:561-6.
8. Rawstron AC, Yuille MR, Fuller J, Cullen M, Kennedy B, Richards SJ, et al. Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion. Blood 2002;100:2289-90.
9. Rawstron AC, Green MJ, Kuzmicki A, Kennedy B, Fenton JA, Evans PA, et al. Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3,5% of adults with normal blood counts. Blood 2002;100:635-9.
10. - B-lymphocyte expansions are frequent in the peripheral blood of the elderly. Blood 2004;103:2337-42.
11. Ghia P, Guida G, Stella S, Gottardi G, Geuna M, Strola G, Scielzo C, Caligaris-Cappio F. The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood 2003;101:1262-9.
12. Vilpo J, Tobin G, Hulkkonen J, Hurme M, Thunberg U, Sundstrom C, Vilpo L, Rosenquist R. Surface antigen expression and correlation with variable heavy-chain gene mutations status in chronic lymphocytic leukemia. Eur J Haematol 2003;70:53-9.
13. Domingo-Domenech E, Domingo-Claros A, Gonzalez-Barca E, Beneitez D, Alonso E, Romagosa V, et al. CD38 expression in B-chronic lymphocytic leukemia: association with clinical presentation and outcome in 155 patients. Haematologica 2002;87:1021-7.
14. D'Arena G, Musto P, Cascavilla N, Dell'Olio M, Di Renzo N, Perla G, et al. CD38 expression correlates with adverse biological features and predicts poor clinical outcome in B-cell chronic lymphocytic leukemia. Leuk Lymphoma 2001;42:109-14.
15. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, et al. ZAP-70 epression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. New Engl J of Med 2003;348:1764-75.
16. Orchard JA, Ibbotson Re, Davis Z, Wiestner A, Rosenwald A, Thomas PW, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004;363:105-11.
17. Rawstron AC, Kennedy B, Evans PA, Davies FE, Richards SJ, Haynes AP, et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 2001;98:29-35.
18. Garnier JL, Stevenson G, Blanc-Brunat N, Touraine JL, Milpied N, Leblond V, Blay JY. Treatment of post-transplant lymphomas with anti-B-cell monoclonal antibodies. Recent Results Cancer Res 2002;159:113-22.
19. Pangalis GA, Dimopoulou MN, Angelopoulou MK, Tsekouras C, Vassilakopoulos TP, Vaiopoulos G, Siakantaris MP. Campath-1H(anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders. Med Oncol 2001;18:99-107.
20. Rawstron AC, Kennedy B, Moreton P, Dickinson AJ, Cullen MJ, Richards J, Jack AS, Hillmen P. Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia. Blood 2004;103:2027-31.
21. Keating MJ, Chiorazzi N, Messmer B, Damle RN, Allen SL, Rai KR, Ferrarini M, Kipps TJ. Biology and treatment of chronic lymphocytic leukemia. Hematology 2003:153-75.
22. San Miguel JF, Vidriales MB, Ocio E, Mateo G, Sanchez-Guijo F, Sanchez ML, et al. Immunophenotypic analysis of Waldenstrom's macroglobulinemia. Semin Oncol 2003;30:187-95.
23. Dogan A, Isaacson PG. Splenic marginal zone lymphoma. Semin Diagn Pathol 2003;20:121-7.
24. Ridley RC, Xiao H, Hata H, Woodliff J, Epstein J, Sanderson RD. Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen. Blood 1993;81:767-74.
25. Rawstron AC, Davies FE, DasGupta R, Ashcroft AJ, Patmore R, Drayson MT, et al. Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood 2002;100:3095-100.
26. Grogan TM, Durie BG, Spier CM, Richter L, Vela E. Myelomonocytic antigen positive multiple myeloma. Blood 1989;73:763-9.
27. Thieblemont C, Berger F, Dumontet C, Moullet I, Bouafia F, Felman P, Salles G, Coiffier B. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood 2000;95:802-6.
28. Camacho FI, Garcia JF, Sanchez-Verde L, Saez AI, Sanchez-Beato M, Mollejo M, Piris MA. Unique phenotypic profile of monocytoid B cells: differences in comparison with the phenotypic profile observed in marginal zone B cells and so-called monocytoid B cell lymphoma. Am J Pathol 2001;158:1363-9.
29. Conconi A, Bertoni F, Pedrinis E, Motta T, Roggero E, Luminari S, et al. Nodal marginal zone B-cell lymphomas may arise from different subsets of marginal zone B lymphocytes. Blood 2001;98:781-6.
30. Dono M, Zup S, Leanza N, Melioli G, Fogli M, Melagrana A, Chiorazzi N, Ferrarini M. Heterogeneity of tonsillar subepithelial B lymphocytes, the splenic marginal zone equivalents. J Immunol 2000;164:5596-604.
31. Stein K, Hummel M, Korbjuhn P, Foss HD, Anagnostopoulos I, Marafioti T, Stein H. Monocytoid B-cells are distinct from splenic marginal zone cells and commonly derive from unmutated naïve B-cells and less frequently from postgerminal center B-cells by polyclonal transformation. Blood 1999;94:2800-8.
32. Oertl J, Kingreen D, Busemann C, Stein H, Dörken B. Morphologic diagnosis of leukaemic B-lymphoproliferative disorders and the role of cyclin D1 expression. J Cancer Res Clin Oncol 2002;128:182-8.
33. Matolcsy A, Chadburn A, Knowles DM. De novo CD5-positive and Richter's syndrome-associated diffuse large B cell lymphomas are genotypically distinct. Am J Pathol 1995;147:207-16.
34. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al.; Lymphoma/Leukemia Molecular Profiling Project. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937-47.
35. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-82.
36. Szremska AP, Kenner L, Weisz E, Ott RG, Passegue E, Artwohl M, et al. JunB inhibits proliferation and transformation in B-lymphoid cells. Blood 2003;102:4159-65.